Magnet Biomedicine partners with Eli Lilly to develop oncology molecular glue therapeutics using TrueGlue platform, aiming to target difficult-to-drug conditions. The collaboration includes significant upfront payment, milestones, and royalties. CEO Safina highlights the potential for breakthrough therapies through this innovative approach.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing